E-Mail
Credit: University of Cincinnati
PORTLAND, OR - A first-of-its-kind randomized clinical trial found that patients with pancreatic cancer didn t live any longer than expected after receiving pre-operative chemotherapy from either of the two standard regimens, according to trial results published in
JAMA Oncology.
While the trial findings did not show a direct patient benefit, they do show that it s possible to safely administer chemotherapy prior to pancreatic cancer surgery. They also pave the way for better treatment testing for this notorious killer. With no symptoms in the early stages, and few effective therapies, pancreatic cancer is the fourth-most deadly cancer type in the United States. According to the American Cancer Society, only 20 percent of pancreatic cancer patients are alive one year after diagnosis. After five years, only about 7 percent are alive.
E-Mail
IMAGE: Dr. Catherine Van Poznak is the co-chair of a new SWOG Cancer Research Network trial that details, for the first time, the incidence of a common bone disease in cancer. view more
Credit: University of Michigan Rogel Cancer Center
PORTLAND, OR - A landmark study by researchers from the SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), has found that 2.8 percent of patients on average develop osteonecrosis of the jaw, or ONJ, within three years of starting a common treatment for cancer that has spread to the bone.